Holding paper receipts for just 10 seconds can pose health risks, researchers warn
In an Apr. 14 statement, the Center for Environmental Health (CEH) announced a notice of violation for 32 retailers that allegedly had high levels of Bisphenol S (BPS) in their receipts.
In the official notice of violation on April 11, the companies named dozens of national corporations.
Men's Multivitamins Recalled Due To Undeclared Allergen: Fda
The organization described Bisphenol S (BPS) as the "lesser-known but harmful chemical cousin to BPA in receipt paper," and described the organic compound as "hormone-disrupting."
"BPS, like [Bisphenol A] … mimics estrogen and can disrupt the normal functioning of the body, including metabolism, growth and development, and reproduction," the statement said.
Read On The Fox News App
"Studies show that BPS can be absorbed through skin when handling receipt paper – even for short periods."
This Odd Dental Habit Could Spark Heart Health Risks, Experts Warn
The statement claimed that holding a BPS-laced receipt for just 10 seconds could have serious health consequences.
"Based on these studies and testing by an independent lab, the concentrations were so high that touching only one receipt with BPS for 10 seconds resulted in exposure above the safe harbor level, which requires a clear and reasonable warning to consumers," CEH Science Lead Mihir Vohra said in the press release.
CEH stated that a lawsuit will be filed against the alleged violators unless they agree to "provide clear and reasonable warnings" to consumers or "reformulate such products to eliminate the BPS exposures."
The retailers will also have to pay an "appropriate civil penalty."
The organization advised consumers to decline paper receipts whenever possible.
Click Here To Sign Up For Our Health Newsletter
"Store workers who must handle receipts should wear gloves if possible or avoid using alcohol-based hand cleaners before handling a receipt, because it can significantly increase the absorption of BPS," said CEH Senior Director Shakoora Azimi-Gaylon in the release.
"Receipts are made from thermal paper, which shouldn't be recycled because they contain bisphenols like BPA and BPS, which can contaminate the recycling stream and pose health and environmental risks."
Fox News senior medical analyst Dr. Marc Siegel noted that digital receipts are more prevalent than ever.
"We are definitely moving in the direction of digital receipts anyway," the medical expert told Fox News Digital.
Siegel also noted that many Americans are exposed to Bisphenol A (BPA) without noticing it – for example, it can commonly be found on smartphone cases, despite not being found on iPhones.
For more Health articles, visit www.foxnews.com/health.
More research needs to be done on the impact of "forever chemicals" like BPS, the doctor suggested.
"Forever chemicals are everywhere and there is a concern about fertility," Siegel cautioned.
"We need to do a better job of documenting and limiting exposure."
BPS has been scrutinized in recent years over its potential to adversely impact people's health.
In 2021, German researchers found that the chemical compound could "seriously damage" human brains after studying its effects on the nerve cells of goldfish.Original article source: Holding paper receipts for just 10 seconds can pose health risks, researchers warn
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. Brinsupri is the first and only FDA-approved treatment for NCFB, a chronic lung condition characterized by permanently widened and damaged airways (bronchi), leading to persistent mucus production, recurrent infections, and difficulty breathing. There are approximately 500,000 people in the U.S. diagnosed with NCFB. The approval is based on data from the Phase 3 ASPEN and Phase 2 WILLOW ASPEN, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also met several exacerbation-related secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the proportion of patients remaining exacerbation-free over the treatment period. Patients who received Brinsupri 25 mg experienced a statistically significantly less decline in lung function, as measured by forced expiratory volume in one second (FEV₁) after using a bronchodilator, at week 52. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions in WILLOW. In parallel, applications for brensocatib with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, and the company plans to file in Japan in 2025. Commercial launches are anticipated in 2026, pending approval in each territory. Price Action: INSM stock is up 6.20% at $119.89 at the last check on Tuesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? INSMED (INSM): Free Stock Analysis Report This article FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNBC
25 minutes ago
- CNBC
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The Food and Drug Administration is weighing revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC on Tuesday. The move could leave many kids with no available shot against the virus, as jabs from Moderna and Novavax are cleared for more limited populations. While Covid typically causes mild symptoms in most children, others, such as infants under 1 or those with certain health conditions, can be at a higher risk of severe illness and hospitalization. If the FDA pulls the authorization, it would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr. — a prominent vaccine skeptic — took the helm. HHS did not immediately respond to a request for comment. The FDA told Pfizer it might not renew its longstanding emergency use authorization for children aged 6 months to 4 years, the company said in a statement. Pfizer said it has requested the authorization to remain in place for the upcoming fall and winter season and is "currently in discussions with the agency on potential paths forward." The company said that the FDA's "deliberations" are not related to the safety and efficacy of the shot, "which continues to demonstrate a favorable profile." The Guardian first reported on the FDA's potential move. Moderna is working with the Centers for Disease Control and Prevention to boost supplies of its own Covid shot for children, the Guardian reported on Saturday. In July, the FDA granted full approval to Moderna's Covid vaccine for children — but only for those with health conditions that may put them at increased risk of severe illness if they become infected. Both shots from Moderna and Pfizer user messenger RNA technology. Kennedy has targeted those vaccines in the past, filing a petition in May 2021 demanding that the agency revoke authorization of the jabs. Meanwhile, Novavax's protein-based shot has never been available for children under 12. In May, Kennedy announced that the Centers for Disease Control and Prevention has removed its recommendation of Covid vaccines for healthy children and pregnant women. But in updated guidance days later, the CDC said the shots "may" be given to those kids if a doctor agreed that it was necessary. Covid vaccines during pregnancy are now listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults.


Bloomberg
27 minutes ago
- Bloomberg
Supergoop Warned by FDA as Part of Crackdown on Mousse Sunscreen
The US Food and Drug Administration warned Supergoop! and other sunscreen manufacturers that products sold in mousse form may not work. 'Beware of sunscreen products in mousse form because they might not be effective,' the agency told consumers in a post on X after it sent warning letters to five companies.